Phase II COSMOS study results published in The Lancet on World Hepatitis Day
The phase II COSMOS study evaluated the interferon-free combination of simeprevir and sofosbuvir in treatment-naïve and prior null-responder patients with all stages of liver fibrosis, including cirrhosis.Stockholm, Sweden — Medivir AB (OMX: MVIR) announces that results from the phase II COSMOS clinical study were published July 28 in The Lancet, demonstrating that 92 percent of genotype 1 chronic hepatitis C virus adult patients treated with simeprevir in combination with sofosbuvir achieved sustained virologic response 12 weeks after the end of treatment (SVR12). The study included